So I think the short answer is we are full speed ahead on our original plan that centers around dermatomyositis where the study continues to enroll. Well, that includes potentially NIU and obviously as Richard said, and as I said earlier, we'll have to make a decision on what to do in NIU after observing that proof-of-concept data coming in the near future. Dennis Ding Matt Gline No, I don't have too much, too much there. I mean, I think, look, I think you both pointed out that there is some variability the ...